Maternal antecedents and outcomes for RhD allo-immunization: a study of brazilian population
Keywords:
blood transfusion, gestational age, Rh immunization, perinatal outcome, pregnancyAbstract
Objective
To evaluate the association between perinatal evolution and maternal antecedents of sensitizing events, in RhD immunized pregnancies in a local population.
Methods
Retrospective analysis of the medical records collected from RhD allo-immunized pregnant women attending the Centro de Atenção Integral à Saúde da Mulher da Universidade Estadual de Campinas for antenatal care, between January 1990 and May 1999. As maternal variables, previous blood transfusions and the lack of anti-D prophylaxis (non anti-D), were analyzed. As perinatal variables: gestational age at delivery, birthweight, fetal blood transfusion and/or fetal death.
Results
The lack of anti-D use was identified in 70% of these women. There were no statistical differences in the rates of fetal death or necessity for fetal blood
transfusions between the previous blood transfusions and non-anti-D groups. The gestational ages and birthweight for the mothers with and without previous blood transfusions were respectively 35.7 and 37.9 weeks (p=0.03) and 2232g and 2784g (p=0.04).
Conclusion
The most frequent antecedent in maternal allo-immunization found in the current study population, was the lack of immuno-prophylaxis. The cause of maternal immunization did not influence the prognosis of pregnancy, except for a reduction in gestational age and birthweight from mothers who had suffered previous blood transfusions.
Downloads
References
Bowmam JM. Hemolytic disease. 4.ed. ln Creasy R, Resnik R, editors. Maternal-Fetal Medicine. Philadelphia: WB Saunders; 1999. p.736-66.
Howard HL, Martkew VJ, McFadyen IR, Clarke CA. Preventing Rhesus D haemolytic disease of the newborn by giving anti-D immunoglobulin: are the guidelines being adequately followed? Br J Obstet Gynecol. 1997; 104(1):37-41.
Flegel WA, Wagner FF. Molecular Biology of partial D and weak D: implications for Blood Bank Practice. Clin Lab 2002; 48(1-2):53-9.
Tannirandorn Y, Rodeck CH. New approaches in the treatment of haemolytic disease of the fetus. Baillieres Clin Haematol. 1990; 3(2):289-320.
Bowman JM. Antenatal suppression of Rh alloimmunization. Clin Obstet Gynecol. 1991; 34(2):296-303.
Schumacher B, Moise Junior KJ. Fetal transfusion for red blood ce/1 alloimmunization in pregnancy. Obstet Gynecol. 1996; 88(1):137-50.
Hussey RM, Clarke CA. Deaths from Rh haemolytic disease in England and Wales in 1988 and 1989. BMJ. 1991; 303(6800):445-6.
Staugenberg M, Selbing A, Lingman G, Westgren M. Rhesus immunization: new perspectives in maternal
-fetal medicine. Obstet Gynecol Surv. 1991; 46(4):189-95.
Costa Ferreira H. Importância das transfusões de sangue como agentes sensibilizantes da doença hemolítica do recém-nascido. The importance of blood transfusion as sensitizing agents on perinatal haemolitic disease of newborn. Rev Clin São Paulo. 1956; 32-5.
Walker W, Murray S. Haemolytic disease of the newborn as a family problem. Br Med J. 1956; 681(4960):187-93.
Portman C, Ludlow J, Joyce A, Chan FY. Antecedents to and outcomes of RH(D) isoimunization: Mater Mother Hospital Brisbone 1988-1995. Aust N Z J Obstet Gynaecol. 1997; 37(1):12-6.
Weiner CP, Williamson RA, Wenstrom KD, Sipes SL, Grant SS, Widness JA. Management of fetal hemolytic disease by cordocentesis. 1. Prediction of fetal anemia. Am J Obstet Gynecol. 1991; 165(3):546-53.
Parer JT. Severe Rh isoimmunization - current methods of in utero diagnosis and treatment. Am J Obstet Gynecol. 1998; 158:1323-9.
Nicolaides KH, Rodeck CH, Mibashan RS, Kemp JR. Have Liley charts outlived their usefulness? Am J Obstet Gynecol. 1986; 155(1):90-4.
